Sudeep Pharma Ltd
- Market Cap ₹ 0.00 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 0.00
- Book Value ₹
- Dividend Yield %
- ROCE 28.6 %
- ROE 25.1 %
- Face Value ₹ 1.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 30.0%
- Market value of investments Rs.0.14 Cr. is more than the Market Cap Rs.0.00 Cr.
Cons
- Company has high debtors of 166 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 218 | 345 | 404 | 344 | 357 | |
| 172 | 277 | 315 | 211 | 224 | |
| Operating Profit | 46 | 68 | 89 | 133 | 133 |
| OPM % | 21% | 20% | 22% | 39% | 37% |
| 4 | 8 | 11 | 8 | 8 | |
| Interest | 1 | 2 | 5 | 4 | 6 |
| Depreciation | 4 | 4 | 5 | 5 | 6 |
| Profit before tax | 45 | 70 | 91 | 132 | 129 |
| Tax % | 22% | 26% | 26% | 26% | 26% |
| 35 | 52 | 67 | 98 | 96 | |
| EPS in Rs | |||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 1% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 23% |
| TTM: | -2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 30% |
| Last Year: | 25% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 10 |
| Reserves | 115 | 167 | 235 | 333 | 418 |
| 31 | 73 | 71 | 60 | 123 | |
| 67 | 92 | 109 | 56 | 54 | |
| Total Liabilities | 214 | 333 | 416 | 451 | 604 |
| 68 | 120 | 90 | 96 | 105 | |
| CWIP | 23 | 4 | 26 | 44 | 88 |
| Investments | 24 | 15 | 19 | 29 | 32 |
| 99 | 194 | 282 | 282 | 380 | |
| Total Assets | 214 | 333 | 416 | 451 | 604 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Net Cash Flow |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 97 | 130 | 114 | 150 | 166 |
| Inventory Days | 66 | 71 | 115 | 131 | 199 |
| Days Payable | 73 | 65 | 86 | 99 | 110 |
| Cash Conversion Cycle | 90 | 136 | 143 | 182 | 255 |
| Working Capital Days | 15 | 37 | 57 | 125 | 140 |
| ROCE % | 37% | 35% | 39% | 29% |
Documents
Annual reports
No data available.